Could Revolution Medicines Be a Millionaire-Maker Stock?

Revolution Medicines' stock has soared over 9x in three years. This success has been driven by excitement about the company's cancer drug, Rasonque.

The Motley Fool • 16 hours ago

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines during the second quarter. The biotech earned approval for an innovative medicine for pancreatic cancer in the third quarter.

The Motley Fool • Oct 27, 2026

Revolution Medicines to Participate in November 2026 Investor Conferences

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in two upcoming investor conferences.

GlobeNewsWire • Oct 27, 2026

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The analyses showed that RASONQUE (daraxonrasib) consistently provided an overall survival (OS) benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma (PDAC), including those with no identified tumor RAS mutation. The OS benefit with RASONQUE was also maintained across preselected standard-of-care (SOC) chemotherapy regimens and prior treatment settings, including early metastatic recurrence following perioperative therapy.

GlobeNewsWire • Oct 23, 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire • Oct 21, 2026

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer.

Benzinga • Oct 20, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inhibitor, in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).

GlobeNewsWire • Oct 20, 2026

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

Revolution Medicines Inc. (NASDAQ:RVMD) has significant growth opportunities beyond pancreatic cancer, according to William Blair, which initiated coverage of the biotechnology company with an Outperform rating and a $226 price forecast.

Benzinga • Oct 16, 2026

EMA recommends approval of Revolution's pancreatic cancer drug

A European Medicines Agency committee on ​Thursday recommended approval of ‌Revolution Medicines' Rasonque in the EU for adults with pancreatic ​cancer that has spread ​and worsened after at least ⁠one prior treatment.

Reuters • Oct 15, 2026

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements across all primary and key secondary endpoints, regardless of tumor RAS mutation status Positive CHMP opinion follows an expedited phased review of RASONQUE under the EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of RASONQUE (daraxonrasib) once-daily oral tablets as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

GlobeNewsWire • Oct 15, 2026